Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL678307 | 0.82 | MEN1 (0.54) | MAPTALDH1A1HTTMEN1KMT2A | |
| SCHEMBL8279098 | 0.80 | ALDH1A1 (0.70) | MAPTALDH1A1LMNAHTTNPC1 | |
| SCHEMBL678581 | 0.80 | MAPT (0.65) | MAPTALDH1A1LMNAHTTMEN1 | |
| SCHEMBL4585596 | 0.80 | ALDH1A1 (0.79) | MAPTALDH1A1LMNAHTT | |
| SCHEMBL21840821 | 0.79 | NPC1 (0.71) | MAPTALDH1A1LMNAHTTNPC1 | |
| SCHEMBL4585958 | 0.79 | ALDH1A1 (0.60) | MAPTALDH1A1LMNAHTTCYP1A2 | |
| SCHEMBL581124 | 0.78 | ALDH1A1 (1.00) | MAPTALDH1A1LMNAHTTNPC1 | |
| SCHEMBL9685976 | 0.77 | MAPT (0.45) | MAPTALDH1A1LMNAHTTNPC1 | |
| SCHEMBL11739607 | 0.77 | ALDH1A1 (0.66) | MAPTALDH1A1LMNAHTTNPC1 | |
| SCHEMBL11739060 | 0.77 | ALDH1A1 (0.66) | MAPTALDH1A1LMNAHTTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951013-B2 | Fucosidase inhibitors | HORIZON ORPHAN LLC (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170029376-A1 | FUCOSIDASE INHIBITORS | RAPTOR PHARMACEUTICALS INC. (US) | 2017-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029376-A1 | FUCOSIDASE INHIBITORS | FUCA1, FUCA2, ENGASE | MAPT 3789/4885ALDH1A1 588/4885LMNA 3460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.